558 related articles for article (PubMed ID: 30327349)
1. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis.
Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG
Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349
[TBL] [Abstract][Full Text] [Related]
2.
Tschida BR; Temiz NA; Kuka TP; Lee LA; Riordan JD; Tierrablanca CA; Hullsiek R; Wagner S; Hudson WA; Linden MA; Amin K; Beckmann PJ; Heuer RA; Sarver AL; Yang JD; Roberts LR; Nadeau JH; Dupuy AJ; Keng VW; Largaespada DA
Cancer Res; 2017 Dec; 77(23):6576-6588. PubMed ID: 28993411
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
5. Carnitine palmitoyltransferase gene upregulation by linoleic acid induces CD4
Brown ZJ; Fu Q; Ma C; Kruhlak M; Zhang H; Luo J; Heinrich B; Yu SJ; Zhang Q; Wilson A; Shi ZD; Swenson R; Greten TF
Cell Death Dis; 2018 May; 9(6):620. PubMed ID: 29795111
[TBL] [Abstract][Full Text] [Related]
6. Two-Step Forward Genetic Screen in Mice Identifies Ral GTPase-Activating Proteins as Suppressors of Hepatocellular Carcinoma.
Kodama T; Bard-Chapeau EA; Newberg JY; Kodama M; Rangel R; Yoshihara K; Ward JM; Jenkins NA; Copeland NG
Gastroenterology; 2016 Aug; 151(2):324-337.e12. PubMed ID: 27178121
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
[TBL] [Abstract][Full Text] [Related]
8. Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis.
Fan Y; Bazai SK; Daian F; Arechederra M; Richelme S; Temiz NA; Yim A; Habermann BH; Dono R; Largaespada DA; Maina F
J Hepatol; 2019 Mar; 70(3):470-482. PubMed ID: 30529386
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Charrez B; Qiao L; Hebbard L
World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.
He Y; Hwang S; Cai Y; Kim SJ; Xu M; Yang D; Guillot A; Feng D; Seo W; Hou X; Gao B
Hepatology; 2019 Oct; 70(4):1150-1167. PubMed ID: 30964207
[TBL] [Abstract][Full Text] [Related]
11. mTOR direct crosstalk with STAT5 promotes de novo lipid synthesis and induces hepatocellular carcinoma.
Li T; Weng J; Zhang Y; Liang K; Fu G; Li Y; Bai X; Gao Y
Cell Death Dis; 2019 Aug; 10(8):619. PubMed ID: 31409773
[TBL] [Abstract][Full Text] [Related]
12. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
13. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice.
Yokohama K; Fukunishi S; Ii M; Nakamura K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
Int J Mol Med; 2016 Nov; 38(5):1499-1506. PubMed ID: 28025996
[TBL] [Abstract][Full Text] [Related]
14. Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma.
Kodama T; Newberg JY; Kodama M; Rangel R; Yoshihara K; Tien JC; Parsons PH; Wu H; Finegold MJ; Copeland NG; Jenkins NA
Proc Natl Acad Sci U S A; 2016 Jun; 113(24):E3384-93. PubMed ID: 27247392
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
[TBL] [Abstract][Full Text] [Related]
16. Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer.
Jeong SH; Kim HB; Kim MC; Lee JM; Lee JH; Kim JH; Kim JW; Park WY; Kim SY; Kim JB; Kim H; Kim JM; Choi HS; Lim DS
J Clin Invest; 2018 Mar; 128(3):1010-1025. PubMed ID: 29400692
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic mutations and dysregulated pathways in obesity-associated hepatocellular carcinoma.
Shen J; Tsoi H; Liang Q; Chu ES; Liu D; Yu AC; Chan TF; Li X; Sung JJ; Wong VW; Yu J
Oncogene; 2016 Dec; 35(49):6271-6280. PubMed ID: 27132506
[TBL] [Abstract][Full Text] [Related]
18. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
19. Sleeping Beauty insertional mutagenesis screen identifies the pro-metastatic roles of CNPY2 and ACTN2 in hepatocellular carcinoma tumor progression.
Lo LH; Lam CY; To JC; Chiu CH; Keng VW
Biochem Biophys Res Commun; 2021 Feb; 541():70-77. PubMed ID: 33482578
[TBL] [Abstract][Full Text] [Related]
20. Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease.
Clarke JD; Novak P; Lake AD; Shipkova P; Aranibar N; Robertson D; Severson PL; Reily MD; Futscher BW; Lehman-McKeeman LD; Cherrington NJ
Dig Dis Sci; 2014 Feb; 59(2):365-74. PubMed ID: 24048683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
